- About About
Medical Patient Resources Becoming a State-Authorized Patient Talking to your doctor Which conditions qualify? The Medical Cannabis Patient’s Guide for U.S. Travel Patient's Guide to CBD Patient's Guide to Medical Cannabis Guide to Using Medical Cannabis Condition-based Booklets Growing Cannabis Cannabis Tincture, Salve, Butter and Oil Recipes Leaf411 Affordability Program Tracking Treatment & Gathering Data with Releaf App Medical Professional Resources CME for Medical Professionals Cannabis Safety Medical Cannabis Research
- Legal Legal
Advocacy ASA Chapters Start an ASA Chapter Take Action Campaigns No Patient Left Behind End Pain, Not Lives Vote Medical Marijuana Medical Cannabis Advocate's Training Center Resources for Tabling and Lobby Days Strategic Planning Civics 101 Strategic Messaging Citizen Lobbying Participating in Implementation Movement Building Organizing a Demonstration Organizing Turnout for Civic Meetings Public Speaking Media 101 Patient's History of Medical Cannabis
Policy Model Federal Legislation Download Ending The Federal Conflict Public Comments by ASA Industry Standards Guide to Regulating Industry Standards Recognizing Science using the Data Quality Act Fact Sheet on ASA's Data Quality Act Petition to HHS Data Quality Act Briefs ASA Data Quality Act petition to HHS Information on Lawyers and Named Patients in the Data Quality Act Lawsuit Reports 2020 State of the States Medical Cannabis in America Medical Cannabis Access for Pain Treatment
- News News
- Join Join
Testing Medical Cannabis
Background: Medical cannabis has been used safely for thousands of years, and there is no evidence to suggests that it represents a real harm to patients. With some medical cannabis laws in the final stages of implementation, more attention has begun to be placed on quality control. Because of the lack of interest and funding at the federal level in performing quality control testing of medical cannabis, such testing has been conducted more independently and at the local level.
Findings: Multiple findings over the years have concluded that cannabis is relatively harmless, not the least of which was from a 1988 Drug Enforcement Administration (DEA) review of marijuana’s classification as a Schedule I drug, in which Chief DEA Administrative Law Judge Francis L. Young stated that, “Marijuana, in its natural form, is one of the safest therapeutically active substances known to man.” Despite reluctance by federal and state governments to conduct quality control testing on medical cannabis, various independent organizations made up of concerned patients, providers, scientists and other experts are working to improve medicine safety and quality by establishing industry standards and guidelines for patients, large-scale cultivators and distributors alike.
Position: Although ASA is not aware of any serious harm that has resulted from consuming cannabis, contaminated or not, we believe that testing can help provide better information to patients about the medication they’re using as well as enhance their choice. Testing should be used as a way to enhance rather than restrict access.
Was this helpful?